8-K: Glaukos Corporation Unveils Investor Presentation, Highlights Innovation and Growth Strategy

Glaukos Corporation presents its investor presentation, emphasizing innovation in chronic eye disease treatments and a core growth strategy focused on leading-edge innovation, dropless therapies, and commercial excellence.

Summary

• Glaukos Corporation presented an investor presentation in March 2025, outlining its strategy and pipeline.
• The company focuses on innovation in chronic eye diseases, with over $700 million invested in R&D since 2018.
• Glaukos has five novel platforms: iStent, iDose, iLink, iLution, and Retina XR, targeting glaucoma, keratoconus, ocular cancer, dry eye, presbyopia, AMD, DME, and RVO.
• Key commercial catalysts for 2025-2026 include iLinko2n with Epioxa for keratoconus and advancements in interventional glaucoma (IG) led by iDose TR.
• iDose TR is designed for continuous drug therapy to address patient non-compliance with topical medications.
• Clinical data shows that 81% of iDose TR subjects in Phase 3 trials were completely free of IOP-lowering topical medications at 12 months.
• Glaukos is also developing Epioxa (Epi-on) for keratoconus, with a PDUFA date set for October 20, 2025.
• The company is advancing multiple transdermal programs targeting dry eye disease, presbyopia, glaucoma and demodex blepharitis using the iLution platform.
• The lead Retina XR program, IVT Multi-Kinase Inhibitor (GLK-401), is in Phase 2 clinical development for AMD, DME, and RVO.
• Glaukos reported net sales of $383 million in 2024 and has a healthy balance sheet with $324 million in cash and equivalents as of December 31, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Glaukos, highlighting its innovative pipeline, strong clinical data, and solid financial position. The focus on addressing unmet needs in chronic eye diseases and the potential for sustained growth contribute to the positive sentiment.

Positives

• Glaukos is focused on innovation and has a robust pipeline of products.
• iDose TR shows promising clinical data in reducing the need for topical medications.
• The company is expanding its product offerings to address various eye diseases.
• Glaukos has a strong financial position with significant cash reserves.
• The company has a global infrastructure with direct operations in 17 countries.

Negatives

• The investor presentation includes forward-looking statements that are subject to risks and uncertainties.
• The company depends on a limited number of third-party suppliers.
• The lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes.

Risks

• The company's ability to successfully commercialize iDose TR therapy is a risk.
• General macroeconomic conditions, including foreign currency fluctuations and future health crises, could impact the business.
• Reliance on third-party suppliers poses a risk to the supply chain.
• Cyber threats and cybersecurity incidents could impact information systems.
• Protecting intellectual property against third parties and competitors is a risk.

Future Outlook

Glaukos aims to establish robust growth engines centered on proven therapies, expand market access, and advance its pipeline programs to create a cascade of new products across various disease categories over the next decade.

Industry Context

Glaukos is positioning itself to disrupt the traditional treatment paradigm for glaucoma with its interventional glaucoma (IG) approach, aiming to reduce the reliance on topical medications and improve patient compliance. The company is also addressing unmet needs in keratoconus and other eye diseases with its innovative platforms.

Comparison to Industry Standards

• Glaukos is competing with companies like Novartis (Travatan Z, Lumigan) in the glaucoma market, aiming to provide a dropless alternative with iDose TR.
• In the keratoconus market, Glaukos's Photrexa is the first and only FDA-approved corneal cross-linking therapy, setting a benchmark for others.
• The company's focus on sustained-release drug delivery aligns with the industry trend towards longer-lasting treatments and improved patient compliance, similar to Allergan's Durysta.

Stakeholder Impact

• Shareholders can expect potential growth and value creation from the company's innovative pipeline and commercial strategies.
• Patients may benefit from new and improved treatments for chronic eye diseases.
• Physicians may have access to new tools and therapies to better manage their patients' conditions.

Next Steps

• Advance enrollment in PMA pivotal trial for iStent infinite.
• Commence US IDE trial for PRESERFLO MicroShunt.
• Conduct Phase 4 studies for iDose TR.
• Advance Phase 2b/3 clinical program for iDose TREX.
• Commence Phase 2 trial for iLution Blepharitis by the end of 2025.
• Secure FDA approval for Epioxa (Epi-on) by the end of 2025.
• Advance Phase 2 clinical program for iLink 3rd Generation.
• Advance enrollment in Phase 2 trial for IVT Multi-Kinase Inhibitor (GLK-401).

Key Dates